Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial

Objective: Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism. Less is known about the long-term effects of risperidone exposure in this population. We examined the tolera...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Child Adolesc Psychopharmacol
Autori principali: Aman, Michael, Rettiganti, Mallikarjuna, Nagaraja, Haikady N., Hollway, Jill A., McCracken, James, McDougle, Christopher J., Tierney, Elaine, Scahill, Lawrence, Arnold, L. Eugene, Hellings, Jessica, Posey, David J., Swiezy, Naomi B., Ghuman, Jaswinder, Grados, Marco, Shah, Bhavik, Vitiello, Benedetto
Natura: Artigo
Lingua:Inglês
Pubblicazione: Mary Ann Liebert, Inc. 2015
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4545698/
https://ncbi.nlm.nih.gov/pubmed/26262903
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cap.2015.0005
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi